{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Computer-Based Problem Solving: Breaking Down Research Challenges\n",
    "\n",
    "**Course:** Molecular Modeling in Drug Design  \n",
    "**Audience:** Masters students in Drug Sciences  \n",
    "\n",
    "---\n",
    "\n",
    "## Welcome Back!\n",
    "\n",
    "In our last session, you learned the fundamental building blocks that make every computer program work:\n",
    "\n",
    "- **Variables** for storing information\n",
    "- **Loops** for repeating actions\n",
    "- **Conditionals** for making decisions\n",
    "- **Files** for permanent storage\n",
    "\n",
    "You also learned about **computational thinking** - the systematic approach to breaking problems into manageable pieces.\n",
    "\n",
    "Today, we're going to put these concepts into practice. You'll face real research problems from different areas of drug sciences and learn to think through solutions step-by-step, **without writing any code yet**.\n",
    "\n",
    "Think of today as planning a complex experiment: before you step into the lab, you need to understand exactly what you're trying to accomplish, what steps you'll take, and how you'll interpret the results.\n",
    "\n",
    "### Today's Research Domains\n",
    "\n",
    "We'll explore problems from four key areas of drug sciences:\n",
    "\n",
    "- **üìä Pharmacovigilance:** Safety signal detection from real-world data\n",
    "- **üß™ In-vitro Research:** Laboratory-based cellular and molecular studies\n",
    "- **üíª In-silico Research:** Computer-based molecular modeling and virtual screening\n",
    "- **üè• Clinical Studies:** Human trial data analysis and optimization\n",
    "\n",
    "This diversity will help you understand how computational thinking applies across the entire drug development pipeline."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "---\n",
    "\n",
    "## Part 1: The Problem-Solving Framework\n",
    "\n",
    "### From Research Question to Solution\n",
    "\n",
    "Every computational problem in research follows the same pattern we discussed before:\n",
    "\n",
    "```\n",
    "RESEARCH QUESTION ‚Üí PROBLEM BREAKDOWN ‚Üí SOLUTION DESIGN ‚Üí IMPLEMENTATION\n",
    "```\n",
    "\n",
    "Today we'll focus on the middle steps: breaking down problems and designing solutions.\n",
    "\n",
    "### The Five-Step Approach\n",
    "\n",
    "When faced with any research problem that could benefit from computation, follow these steps:\n",
    "\n",
    "**1. Understand the Problem**\n",
    "- What exactly are you trying to find out?\n",
    "- What data do you have available?\n",
    "- What would a successful result look like?\n",
    "\n",
    "**2. Break It Down (Decomposition)**\n",
    "- What smaller sub-problems can you identify?\n",
    "- Which parts can be solved independently?\n",
    "- What's the logical order for solving each piece?\n",
    "\n",
    "**3. Identify Patterns (Pattern Recognition)**\n",
    "- Are there repeated calculations or processes?\n",
    "- Which steps will need to be applied to multiple data points?\n",
    "- What standard approaches exist for similar problems?\n",
    "\n",
    "**4. Design the Solution (Algorithm Design)**\n",
    "- What sequence of steps will solve each sub-problem?\n",
    "- What decisions need to be made along the way?\n",
    "- How will you handle edge cases or errors?\n",
    "\n",
    "**5. Plan the Output (Results and Visualization)**\n",
    "- How will you present your findings?\n",
    "- What visualizations will best communicate your results?\n",
    "- What files or reports need to be generated?\n",
    "\n",
    "### Why This Systematic Approach Matters\n",
    "\n",
    "**Without systematic thinking:**\n",
    "- You might start coding before understanding the problem fully\n",
    "- Important edge cases get overlooked\n",
    "- Solutions are harder to explain or reproduce\n",
    "- Results may not actually answer your research question\n",
    "\n",
    "**With systematic thinking:**\n",
    "- Clear understanding of what you're solving\n",
    "- More efficient solutions\n",
    "- Easier to troubleshoot when things go wrong\n",
    "- Better communication with collaborators\n",
    "- More confidence in your results"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "---\n",
    "\n",
    "## Part 2: Easy Problems - Building Foundation Skills\n",
    "\n",
    "Let's start with straightforward problems that introduce basic concepts. These problems focus on **reading data**, **basic statistical analysis**, and **writing results**.\n",
    "\n",
    "### Problem 1: Pharmacovigilance - Adverse Event Signal Detection\n",
    "\n",
    "**The Research Context:**\n",
    "You work for a regulatory agency analyzing spontaneous adverse event reports. A new diabetes medication has been on the market for 6 months, and you've received 2,847 adverse event reports. You need to identify potential safety signals by comparing the reporting rates of different adverse events for this drug versus the background rates in the database.\n",
    "\n",
    "**Your Task:**\n",
    "Analyze the adverse event data to identify statistically significant safety signals and classify them by severity and clinical importance for regulatory review.\n",
    "\n",
    "**Available Data:**\n",
    "- File: `adverse_events_database.csv`\n",
    "- Contains: Report ID, drug name, adverse event term, patient age, gender, outcome severity\n",
    "- Background database with historical rates for each adverse event\n",
    "- Drug exposure estimates from prescription data\n",
    "\n",
    "### Discussion Exercise 1 (10 minutes)\n",
    "\n",
    "**Work in pairs and discuss:**\n",
    "\n",
    "1. **Understand the Problem:** What constitutes a \"safety signal\" in pharmacovigilance?\n",
    "\n",
    "2. **Break It Down:** What are the individual steps you need to take?\n",
    "\n",
    "3. **Identify Patterns:** What calculations will you repeat for each adverse event?\n",
    "\n",
    "4. **Design the Solution:** What's your step-by-step approach?\n",
    "\n",
    "5. **Plan the Output:** How should you present results to regulatory reviewers? What visualization would help them prioritize investigations?\n",
    "\n",
    "**Think about:** How would you distinguish between a true safety signal and random fluctuation in reporting?\n",
    "\n",
    "### Example Visualization for Problem 1\n",
    "\n",
    "When analyzing adverse events, a **volcano plot** is particularly effective for regulatory review:\n",
    "\n",
    "[6]\n",
    "\n",
    "This visualization immediately shows:\n",
    "- **Statistical significance** (y-axis): How confident we are in the signal\n",
    "- **Effect size** (x-axis): How much the reporting rate has increased\n",
    "- **Prioritization**: Red points in the upper right require immediate investigation\n",
    "- **Context**: Most events (blue points) show no concerning pattern\n",
    "\n",
    "**Why this works for regulators:**\n",
    "- Quick identification of high-priority signals\n",
    "- Clear separation of statistical vs. clinical significance\n",
    "- Easy to communicate to non-technical stakeholders"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Problem 2: In-vitro Research - Multi-plate Cell Viability Analysis\n",
    "\n",
    "**The Research Context:**\n",
    "You're conducting a large-scale cytotoxicity screen using multiple cell lines to assess compound selectivity. You've tested 384 compounds across 6 different cancer cell lines using 96-well plates. Each compound was tested in triplicate, and you need to normalize data between plates and identify compounds with selective toxicity profiles.\n",
    "\n",
    "**Your Task:**\n",
    "Process the multi-plate data, normalize for inter-plate variability, calculate selectivity indices, and identify compounds that show preferential toxicity toward specific cell lines.\n",
    "\n",
    "**Available Data:**\n",
    "- File: `multiplate_viability_data.csv`\n",
    "- Contains: Plate ID, compound ID, cell line, well position, viability percentage, replicate number\n",
    "- Positive and negative controls on each plate\n",
    "- Some wells may have pipetting errors or contamination\n",
    "\n",
    "### Discussion Exercise 2 (10 minutes)\n",
    "\n",
    "**Work in pairs and discuss:**\n",
    "\n",
    "1. Why is plate-to-plate normalization critical in this experiment?\n",
    "2. How would you identify and handle outliers or failed wells?\n",
    "3. What metrics would you use to quantify \"selectivity\" between cell lines?\n",
    "4. How should you visualize both individual compound profiles and overall screening results?\n",
    "\n",
    "**Think about:** What quality control checks would you implement to ensure data reliability across multiple plates and cell lines?\n",
    "\n",
    "### Example Visualizations for Problem 2\n",
    "\n",
    "For multi-cell line screening, **heatmaps** provide an excellent overview of compound selectivity:\n",
    "\n",
    "[7]\n",
    "\n",
    "This visualization reveals:\n",
    "- **Selective compounds** (Compounds 2, 3, 4, 5, 6): Show toxicity in specific cell lines\n",
    "- **Pan-toxic compounds** (Compounds 7, 14, 19): Toxic across all cell lines\n",
    "- **Inactive compounds** (Compounds 8, 15): No significant toxicity\n",
    "\n",
    "For detailed analysis, **dose-response curves** show compound potency:\n",
    "\n",
    "[13]\n",
    "\n",
    "**Why these visualizations work for medicinal chemists:**\n",
    "- Immediate identification of selective vs. non-selective compounds\n",
    "- Clear potency ranking with IC50 values\n",
    "- Quality assessment through curve fitting\n",
    "- Easy comparison across multiple compounds"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "---\n",
    "\n",
    "## Part 3: Medium Problems - Adding Logic and Iteration\n",
    "\n",
    "These problems introduce **simple loops and conditionals** while building on statistical analysis skills.\n",
    "\n",
    "### Problem 3: In-silico Research - Virtual Screening Analysis\n",
    "\n",
    "**The Research Context:**\n",
    "You've performed molecular docking of 50,000 compounds from the ZINC database against a protein target. Each compound has multiple possible binding poses, and you need to analyze the docking results to identify promising hits. The docking software provides binding scores, interaction types, and binding site information for each pose.\n",
    "\n",
    "**Your Task:**\n",
    "Process the docking results to select the best poses, filter compounds based on drug-likeness criteria, cluster similar compounds, and rank potential hits for experimental testing.\n",
    "\n",
    "**Available Data:**\n",
    "- File: `docking_results.csv`\n",
    "- Contains: Compound ID, SMILES string, pose number, binding score, key interactions, molecular weight, logP\n",
    "- Reference data for known active compounds\n",
    "- Some docking runs may have failed to produce valid poses\n",
    "\n",
    "### Discussion Exercise 3 (15 minutes)\n",
    "\n",
    "**Work in groups of 3-4 and discuss:**\n",
    "\n",
    "1. **Data Processing:** How would you handle compounds with multiple poses? What if some compounds have no valid poses?\n",
    "\n",
    "2. **Filtering Criteria:** What drug-likeness filters would you apply (Lipinski's Rule of Five, PAINS, etc.)?\n",
    "\n",
    "3. **Decision Logic:** How would you decide between different poses for the same compound?\n",
    "\n",
    "4. **Similarity Clustering:** How would you group structurally similar compounds to ensure chemical diversity in your final selection?\n",
    "\n",
    "5. **Validation:** How would you assess whether your virtual screening is identifying reasonable hits?\n",
    "\n",
    "**Think about:** What makes this problem more complex than simple data filtering? How many nested decision points can you identify?\n",
    "\n",
    "### Example Visualizations for Problem 3\n",
    "\n",
    "Virtual screening requires multiple visualizations to assess performance and select compounds.\n",
    "\n",
    "**Score distribution** shows the filtering strategy:\n",
    "\n",
    "[8]\n",
    "\n",
    "This histogram reveals:\n",
    "- **Overall distribution**: Most compounds score poorly (normal for virtual screening)\n",
    "- **Selection threshold**: -8.5 kcal/mol captures top 5% of compounds\n",
    "- **Hit enrichment**: Clear separation between promising and unpromising compounds\n",
    "\n",
    "**ROC curve validation** assesses screening quality:\n",
    "\n",
    "[12]\n",
    "\n",
    "**Why these visualizations work for computational chemists:**\n",
    "- **Distribution plot**: Validates scoring function and selection criteria\n",
    "- **ROC curve**: Demonstrates enrichment of known actives\n",
    "- **Quantitative assessment**: AUC = 0.78 shows good but not perfect performance\n",
    "- **Selection guidance**: Top 5% provides best balance of hit rate and false positives"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Problem 4: Clinical Research - Biomarker Time-Course Analysis\n",
    "\n",
    "**The Research Context:**\n",
    "You're analyzing data from a Phase II clinical trial testing a novel anti-inflammatory drug. Blood samples were collected at multiple time points (baseline, 2h, 6h, 24h, 48h, 1 week, 2 weeks) from 120 patients to measure 15 different inflammatory biomarkers. You need to identify which biomarkers respond to treatment and determine optimal sampling strategies for future trials.\n",
    "\n",
    "**Your Task:**\n",
    "Analyze the longitudinal biomarker data to identify treatment-responsive markers, classify response patterns (early/late, transient/sustained), and recommend optimal time points for future pharmacodynamic assessments.\n",
    "\n",
    "**Available Data:**\n",
    "- File: `clinical_biomarker_timecourse.csv`\n",
    "- Contains: Patient ID, treatment group (drug/placebo), time point, biomarker name, concentration, demographic data\n",
    "- Some patients dropped out or missed visits\n",
    "- Laboratory quality control flags for some measurements\n",
    "\n",
    "### Discussion Exercise 4 (15 minutes)\n",
    "\n",
    "**Work in groups and discuss:**\n",
    "\n",
    "1. **Clinical Significance:** How would you distinguish statistically significant changes from clinically meaningful changes?\n",
    "\n",
    "2. **Missing Data:** How would you handle patients who missed visits or dropped out? What's the minimum data needed for each patient?\n",
    "\n",
    "3. **Response Classification:** How would you automatically classify biomarker response patterns?\n",
    "\n",
    "4. **Optimization Question:** If you could only measure biomarkers at 3 time points in future studies, which would you choose and how would you determine this?\n",
    "\n",
    "5. **Regulatory Considerations:** What additional analyses might regulatory agencies require for these pharmacodynamic data?\n",
    "\n",
    "**Think about:** This problem involves patient heterogeneity, multiple comparisons, and regulatory requirements. What are the different layers of complexity?\n",
    "\n",
    "### Example Visualization for Problem 4\n",
    "\n",
    "**Time-course plots** are essential for understanding biomarker kinetics:\n",
    "\n",
    "[9]\n",
    "\n",
    "This visualization shows different response patterns:\n",
    "- **CRP**: Early and sustained decrease (ideal biomarker)\n",
    "- **IL-6**: Rapid decrease (good for early assessment)\n",
    "- **TNF-Œ±**: Delayed decrease (mechanism-related)\n",
    "- **ESR**: Gradual decrease (traditional inflammatory marker)\n",
    "\n",
    "**Why this works for clinical researchers:**\n",
    "- **Clear treatment effects**: Separation between drug and placebo groups\n",
    "- **Kinetic patterns**: Different biomarkers show distinct time courses\n",
    "- **Clinical relevance**: Magnitude and timing of responses inform dosing\n",
    "- **Future design**: Identifies optimal sampling times for Phase III"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "---\n",
    "\n",
    "## Part 4: Hard Problems - Complex Logic and Optimization\n",
    "\n",
    "These problems require **complex loops and conditionals**, **sophisticated statistical analysis**, and **optimization thinking**.\n",
    "\n",
    "### Problem 5: In-vitro Research - Complex Drug Interaction Network Analysis\n",
    "\n",
    "**The Research Context:**\n",
    "You're studying drug interactions in a complex polypharmacy scenario. You've tested all pairwise and three-way combinations of 8 cardiovascular drugs across 4 different cell-based assays (hepatotoxicity, cardiotoxicity, efficacy, and drug metabolism). Each combination was tested at 3 concentration levels with multiple replicates. You need to identify dangerous interactions, beneficial synergies, and predict higher-order interactions.\n",
    "\n",
    "**Your Task:**\n",
    "Analyze the complex interaction network to identify synergistic and antagonistic combinations, predict three-way interactions from pairwise data, assess safety margins, and provide dosing recommendations for clinical combination therapies.\n",
    "\n",
    "**Available Data:**\n",
    "- File: `drug_interaction_network.csv`\n",
    "- Contains: Drug A, Drug B, Drug C (if applicable), concentration levels, assay type, response value, replicate\n",
    "- Individual drug dose-response data for each assay\n",
    "- Known clinical interaction data for validation\n",
    "\n",
    "### Discussion Exercise 5 (20 minutes)\n",
    "\n",
    "**Work in groups of 4-5 and tackle these challenges:**\n",
    "\n",
    "1. **Multi-dimensional Analysis:** How would you organize data with multiple drugs, concentrations, assays, and replicates?\n",
    "\n",
    "2. **Interaction Prediction:** How would you predict three-way interactions from pairwise data? What assumptions are you making?\n",
    "\n",
    "3. **Safety Assessment:** How would you integrate toxicity and efficacy data to assess therapeutic windows for combinations?\n",
    "\n",
    "4. **Clinical Translation:** How would you translate in-vitro interaction data to clinical dosing recommendations?\n",
    "\n",
    "5. **Validation Strategy:** How would you validate your predictions against known clinical interaction data?\n",
    "\n",
    "6. **Computational Efficiency:** With hundreds of possible combinations, how would you design efficient analysis workflows?\n",
    "\n",
    "**Think about:** This problem involves network effects, multiple endpoints, and clinical translation challenges. How many different types of decisions and validations are needed?\n",
    "\n",
    "### Example Visualization for Problem 5\n",
    "\n",
    "**Network diagrams** effectively communicate complex drug interactions:\n",
    "\n",
    "[10]\n",
    "\n",
    "This network visualization reveals:\n",
    "- **Dangerous interactions** (red edges): Warfarin-Clopidogrel, Digoxin-Furosemide\n",
    "- **Beneficial synergies** (green edges): Metoprolol-Lisinopril, Lisinopril-Furosemide\n",
    "- **Neutral combinations** (gray edges): No significant interaction\n",
    "- **Hub drugs**: Some drugs (like Warfarin) have multiple interactions\n",
    "\n",
    "**Why this works for clinical pharmacologists:**\n",
    "- **System-level view**: Shows interaction patterns across multiple drugs\n",
    "- **Risk assessment**: Immediately identifies dangerous combinations\n",
    "- **Clinical guidance**: Highlights beneficial combinations to leverage\n",
    "- **Complexity management**: Simplifies complex interaction data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Problem 6: Clinical Research - Adaptive Platform Trial Optimization\n",
    "\n",
    "**The Research Context:**\n",
    "You're designing an adaptive platform trial for COVID-19 treatments where multiple drugs can be tested simultaneously, with the ability to add new treatments, drop ineffective ones, and modify randomization ratios based on accumulating efficacy and safety data. The trial must maintain statistical rigor while maximizing patient benefit and minimizing exposure to ineffective treatments.\n",
    "\n",
    "**Your Task:**\n",
    "Create a comprehensive simulation framework that models patient enrollment, multiple treatment arms, interim analyses, adaptive decisions, and regulatory requirements. The simulation should optimize the platform design across thousands of scenarios while maintaining statistical power and Type I error control.\n",
    "\n",
    "**Available Data:**\n",
    "- Historical hospitalization and mortality rates for COVID-19\n",
    "- Preliminary efficacy estimates for candidate treatments\n",
    "- Patient enrollment projections and seasonal variations\n",
    "- Regulatory guidelines for adaptive platform trials\n",
    "\n",
    "### Discussion Exercise 6 (25 minutes)\n",
    "\n",
    "**This is the most complex problem. Work in groups of 4-5:**\n",
    "\n",
    "1. **Platform Trial Complexity:** How would you structure a simulation that handles:\n",
    "   - Multiple treatments entering/leaving the platform\n",
    "   - Shared control arms across treatments\n",
    "   - Different patient populations and endpoints\n",
    "   - Regulatory oversight and stopping rules\n",
    "\n",
    "2. **Adaptive Algorithms:** What decision rules would you implement for:\n",
    "   - Adding new treatments to the platform\n",
    "   - Dropping treatments for futility or safety\n",
    "   - Modifying randomization ratios\n",
    "   - Sharing control data across treatments\n",
    "\n",
    "3. **Statistical Challenges:** How would you address:\n",
    "   - Multiple comparisons across treatments\n",
    "   - Type I error control with adaptive modifications\n",
    "   - Power calculations for varying treatment effects\n",
    "   - Borrowing strength across related treatments\n",
    "\n",
    "4. **Regulatory Requirements:** How would you ensure:\n",
    "   - Transparent pre-specification of adaptation rules\n",
    "   - Audit trails for all adaptive decisions\n",
    "   - Safety monitoring across the platform\n",
    "   - Interpretable results for regulatory review\n",
    "\n",
    "5. **Real-world Implementation:** How would you address:\n",
    "   - Site coordination across multiple treatments\n",
    "   - Patient consent for adaptive randomization\n",
    "   - Supply chain management for multiple drugs\n",
    "   - Communication with investigators and sponsors\n",
    "\n",
    "**Challenge Question:** How would you balance the competing demands of statistical rigor, operational feasibility, patient benefit, and regulatory acceptance in your platform design?\n",
    "\n",
    "### Example Visualization for Problem 6\n",
    "\n",
    "**Operating characteristics plots** show the trade-offs in adaptive design:\n",
    "\n",
    "[11]\n",
    "\n",
    "This visualization demonstrates:\n",
    "- **Power vs. efficiency trade-off**: More frequent analyses increase power but reduce efficiency\n",
    "- **Optimal design point**: Every 100 patients balances power (85%) and sample size (398)\n",
    "- **Decision support**: Clear guidance for design parameter selection\n",
    "- **Regulatory communication**: Transparent presentation of design characteristics\n",
    "\n",
    "**Why this works for regulatory agencies:**\n",
    "- **Transparent trade-offs**: Shows consequences of design decisions\n",
    "- **Statistical validation**: Demonstrates adequate power and controlled error rates\n",
    "- **Optimization rationale**: Clear justification for chosen parameters\n",
    "- **Predictable performance**: Expected outcomes under different scenarios"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "---\n",
    "\n",
    "## Part 5: The Art and Science of Visualization\n",
    "\n",
    "Throughout today's problems, you've seen how **visualization choices directly impact research communication**. Let's explore this critical skill more deeply across different research domains.\n",
    "\n",
    "### Why Visualization Choices Matter Across Research Domains\n",
    "\n",
    "**The same data can tell completely different stories depending on how you present it, and different research domains have different visualization needs:**\n",
    "\n",
    "- **Pharmacovigilance:** Regulatory reviewers need clear safety signals and risk quantification\n",
    "- **In-vitro Research:** Laboratory scientists need detailed experimental validation and quality control\n",
    "- **In-silico Research:** Computational researchers need algorithm performance and molecular insights\n",
    "- **Clinical Research:** Clinicians, regulators, and patients need interpretable treatment effects\n",
    "\n",
    "### The Visualization Decision Framework\n",
    "\n",
    "For every analysis, ask yourself these questions:\n",
    "\n",
    "**1. What is the primary message?**\n",
    "- Are you comparing groups?\n",
    "- Showing relationships between variables?\n",
    "- Demonstrating changes over time?\n",
    "- Highlighting outliers or patterns?\n",
    "\n",
    "**2. Who is your audience?**\n",
    "- Research colleagues who understand the methods?\n",
    "- Clinicians who need practical insights?\n",
    "- Regulatory reviewers who need to verify claims?\n",
    "- General scientific audience?\n",
    "\n",
    "**3. What level of detail is appropriate?**\n",
    "- Summary view for main findings?\n",
    "- Detailed view showing individual data points?\n",
    "- Multiple views for different aspects?\n",
    "\n",
    "### Domain-Specific Visualization Strategies\n",
    "\n",
    "**Problem 1 (Pharmacovigilance - Adverse Events):**\n",
    "- **Primary audience:** Regulatory reviewers, safety scientists\n",
    "- **Best approach:** Volcano plots with significance thresholds [6]\n",
    "- **Why:** Immediate identification of signals requiring investigation\n",
    "- **Regulatory focus:** Must show uncertainty and avoid false alarms\n",
    "\n",
    "**Problem 2 (In-vitro - Cell Viability):**\n",
    "- **Primary audience:** Laboratory researchers, medicinal chemists\n",
    "- **Best approach:** Selectivity heatmaps [7] and dose-response curves [13]\n",
    "- **Why:** Easy comparison of compound profiles and potency assessment\n",
    "- **Research focus:** Experimental validation and reproducibility\n",
    "\n",
    "**Problem 3 (In-silico - Virtual Screening):**\n",
    "- **Primary audience:** Computational chemists, structural biologists\n",
    "- **Best approach:** Score distributions [8] and ROC curves [12]\n",
    "- **Why:** Algorithm validation and performance quantification\n",
    "- **Computational focus:** Method validation and hit enrichment\n",
    "\n",
    "**Problem 4 (Clinical - Biomarkers):**\n",
    "- **Primary audience:** Clinicians, regulatory agencies, clinical researchers\n",
    "- **Best approach:** Time-course plots with clinical thresholds [9]\n",
    "- **Why:** Clinical relevance and treatment monitoring utility\n",
    "- **Clinical focus:** Patient benefit and clinical decision-making\n",
    "\n",
    "**Problem 5 (In-vitro - Drug Interactions):**\n",
    "- **Primary audience:** Clinical pharmacologists, physicians\n",
    "- **Best approach:** Network diagrams showing interaction patterns [10]\n",
    "- **Why:** System-level view of complex interactions\n",
    "- **Safety focus:** Risk communication and clinical guidance\n",
    "\n",
    "**Problem 6 (Clinical - Platform Trials):**\n",
    "- **Primary audience:** Regulatory agencies, biostatisticians\n",
    "- **Best approach:** Operating characteristics plots [11]\n",
    "- **Why:** Design optimization and regulatory approval\n",
    "- **Regulatory focus:** Statistical rigor and transparent trade-offs\n",
    "\n",
    "### Common Visualization Mistakes to Avoid\n",
    "\n",
    "**1. Chart Junk:** Unnecessary 3D effects, excessive colors, or decorative elements that don't add information\n",
    "\n",
    "**2. Wrong Chart Type:** Using a pie chart for more than 3-4 categories, or a line chart for categorical data\n",
    "\n",
    "**3. Missing Context:** No error bars, no sample sizes, no reference points for interpretation\n",
    "\n",
    "**4. Poor Scaling:** Y-axis that doesn't start at zero when it should, or logarithmic scales without clear indication\n",
    "\n",
    "**5. Information Overload:** Trying to show too much in a single plot\n",
    "\n",
    "**6. Domain Mismatch:** Using academic-style plots for regulatory audiences, or oversimplified plots for technical peers\n",
    "\n",
    "### Interactive Exercise: Multi-Audience Visualization (15 minutes)\n",
    "\n",
    "**Work in pairs. Consider the virtual screening problem (Problem 3):**\n",
    "\n",
    "You need to present your results to three different audiences:\n",
    "1. **Computational team:** Needs algorithm validation and performance metrics\n",
    "2. **Medicinal chemists:** Wants to understand chemical diversity and synthetic feasibility\n",
    "3. **Project managers:** Needs timelines, resource requirements, and success probability\n",
    "\n",
    "**For each audience:**\n",
    "- What would be the most important message to communicate?\n",
    "- What type of visualization would be most effective?\n",
    "- What technical details should you include or exclude?\n",
    "- How would you handle the complexity of 50,000 compounds?\n",
    "\n",
    "**Discuss:** How might the same virtual screening analysis require completely different presentations?"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "---\n",
    "\n",
    "## Part 6: Bringing It All Together\n",
    "\n",
    "### What You've Accomplished Today\n",
    "\n",
    "You've worked through six increasingly complex problems that demonstrate computational thinking across the entire drug development pipeline:\n",
    "\n",
    "‚úÖ **Problem decomposition:** Breaking complex research questions into manageable steps\n",
    "\n",
    "‚úÖ **Algorithm design:** Creating systematic approaches to data analysis\n",
    "\n",
    "‚úÖ **Decision logic:** Implementing sophisticated conditional reasoning\n",
    "\n",
    "‚úÖ **Domain expertise:** Understanding how computational approaches differ across research areas\n",
    "\n",
    "‚úÖ **Quality control:** Designing robust validation and error-handling strategies\n",
    "\n",
    "‚úÖ **Visualization strategy:** Choosing appropriate presentations for different audiences\n",
    "\n",
    "### The Research Domain Progression\n",
    "\n",
    "**Easy Problems:**\n",
    "- **Pharmacovigilance** (Problem 1): Population-level safety surveillance\n",
    "- **In-vitro Research** (Problem 2): Controlled laboratory experimentation\n",
    "\n",
    "**Medium Problems:**\n",
    "- **In-silico Research** (Problem 3): Computational prediction and filtering\n",
    "- **Clinical Research** (Problem 4): Human trial data with regulatory implications\n",
    "\n",
    "**Hard Problems:**\n",
    "- **In-vitro Research** (Problem 5): Complex multi-factorial laboratory studies\n",
    "- **Clinical Research** (Problem 6): Adaptive trial design with regulatory oversight\n",
    "\n",
    "### Cross-Domain Insights for Research Success\n",
    "\n",
    "**1. Data Quality is Universal**\n",
    "Whether analyzing adverse events, cell viability, docking scores, or clinical biomarkers, robust quality control is essential. The specific checks vary by domain, but the systematic approach is the same.\n",
    "\n",
    "**2. Validation Strategies Differ by Domain**\n",
    "- **Pharmacovigilance:** Historical comparison and statistical significance\n",
    "- **In-vitro:** Experimental controls and reproducibility\n",
    "- **In-silico:** Known actives and algorithm benchmarking\n",
    "- **Clinical:** Patient outcomes and regulatory standards\n",
    "\n",
    "**3. Audience Awareness is Critical**\n",
    "The same computational analysis might need to satisfy laboratory scientists, regulatory reviewers, clinicians, and patients - each with different needs and expertise levels.\n",
    "\n",
    "**4. Visualization Drives Communication**\n",
    "As you've seen today, the right visualization can make complex data immediately interpretable, while the wrong choice can obscure important findings.\n",
    "\n",
    "**5. Regulatory Requirements Shape Analysis**\n",
    "Understanding regulatory expectations in each domain influences how you design, validate, and present computational analyses.\n",
    "\n",
    "### Looking Ahead: From Thinking to Implementation\n",
    "\n",
    "**Next Week: Python Programming**\n",
    "You'll learn to translate the domain-specific problem-solving frameworks you've developed today into actual Python code. The diversity of today's problems will help you see how the same programming concepts apply across all areas of drug sciences.\n",
    "\n",
    "**What to expect:**\n",
    "- Converting your step-by-step solutions into working code\n",
    "- Learning Python syntax through diverse problem-solving contexts\n",
    "- Using AI tools effectively to implement your designs across different domains\n",
    "- Creating the visualizations you've planned today\n",
    "\n",
    "**Why today's diversity matters:**\n",
    "- You understand the breadth of computational applications in drug sciences\n",
    "- You've seen how the same logical principles apply across different research contexts\n",
    "- You're prepared to work in interdisciplinary teams spanning all areas of drug development\n",
    "- You can communicate computational concepts to diverse audiences\n",
    "\n",
    "### Final Reflection Exercise (10 minutes)\n",
    "\n",
    "**Individual reflection:**\n",
    "\n",
    "1. **Domain Connections:** Which research domain resonated most with your interests, and how might you apply computational thinking in that area?\n",
    "\n",
    "2. **Visualization Insights:** Which visualization example was most helpful for understanding the problem? Why?\n",
    "\n",
    "3. **Cross-Domain Patterns:** What similarities did you notice in problem-solving approaches across different domains?\n",
    "\n",
    "4. **Career Implications:** How might understanding computational approaches across all domains help you in your future career, regardless of your specialization?\n",
    "\n",
    "**Write down one specific way** you could apply today's computational thinking to bridge between different research domains in drug sciences.\n",
    "\n",
    "### The Bigger Picture: Integrated Drug Development\n",
    "\n",
    "Today's session demonstrates that computational thinking is not confined to \"computational\" research - it's a fundamental skill that enhances every aspect of drug development:\n",
    "\n",
    "- **Pharmacovigilance** informs **clinical trial** design\n",
    "- **In-silico** predictions guide **in-vitro** experimentation\n",
    "- **In-vitro** results validate **computational** models\n",
    "- **Clinical** data feeds back to improve **safety surveillance**\n",
    "\n",
    "Understanding how computational approaches work across all these domains positions you to contribute to integrated, efficient drug development processes.\n",
    "\n",
    "**Ready for Implementation**\n",
    "\n",
    "You now have problem-solving frameworks that span the entire drug development pipeline. Next week, we'll transform your systematic thinking into working Python code that can tackle real problems across all areas of drug sciences.\n",
    "\n",
    "The future of drug development lies in seamless integration across domains - and you're prepared to be part of that integration."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "---\n",
    "\n",
    "## Summary: Problem-Solving Patterns Across Research Domains\n",
    "\n",
    "### Universal Patterns That Apply Everywhere\n",
    "\n",
    "**1. The Data Processing Pattern**\n",
    "```\n",
    "Read data ‚Üí Validate quality ‚Üí Process systematically ‚Üí Generate results\n",
    "```\n",
    "*Applied in: All domains, adapted for each context*\n",
    "\n",
    "**2. The Quality Control Pattern**\n",
    "```\n",
    "Define quality criteria ‚Üí Check each data point ‚Üí Flag issues ‚Üí \n",
    "Apply corrections or exclusions ‚Üí Document decisions\n",
    "```\n",
    "*Critical across: Pharmacovigilance, in-vitro, in-silico, and clinical research*\n",
    "\n",
    "**3. The Statistical Analysis Pattern**\n",
    "```\n",
    "Specify hypothesis ‚Üí Choose appropriate test ‚Üí Check assumptions ‚Üí \n",
    "Perform analysis ‚Üí Interpret results ‚Üí Assess clinical significance\n",
    "```\n",
    "*Domain-specific variations in: Test selection, significance thresholds, clinical relevance*\n",
    "\n",
    "**4. The Validation Pattern**\n",
    "```\n",
    "Define validation criteria ‚Üí Apply internal checks ‚Üí \n",
    "Compare with external standards ‚Üí Document reliability\n",
    "```\n",
    "*Domain-specific approaches: Historical data, experimental controls, benchmarks, clinical outcomes*\n",
    "\n",
    "**5. The Decision Support Pattern**\n",
    "```\n",
    "Analyze data ‚Üí Apply decision rules ‚Üí Rank/classify results ‚Üí \n",
    "Provide recommendations ‚Üí Communicate uncertainty\n",
    "```\n",
    "*Audience-specific adaptations: Regulators, researchers, clinicians, patients*\n",
    "\n",
    "### Domain-Specific Considerations\n",
    "\n",
    "| Domain | Key Focus | Primary Challenges | Success Metrics | Key Visualizations |\n",
    "|--------|-----------|-------------------|-----------------|-------------------|\n",
    "| **Pharmacovigilance** | Safety signals | Statistical vs clinical significance | Patient safety improvement | Volcano plots, forest plots |\n",
    "| **In-vitro Research** | Experimental validity | Reproducibility, controls | Predictive accuracy | Heatmaps, dose-response curves |\n",
    "| **In-silico Research** | Computational accuracy | Algorithm performance | Experimental confirmation | Score distributions, ROC curves |\n",
    "| **Clinical Research** | Patient outcomes | Regulatory compliance | Treatment efficacy/safety | Time-course plots, operating characteristics |\n",
    "\n",
    "### Questions That Guide Cross-Domain Problem-Solving\n",
    "\n",
    "**Before Starting Any Analysis:**\n",
    "- What regulatory or ethical constraints apply in this domain?\n",
    "- Who are the key stakeholders and what do they need?\n",
    "- What domain-specific quality standards must be met?\n",
    "- What visualization will best communicate results to my audience?\n",
    "\n",
    "**During Problem-Solving:**\n",
    "- How does this analysis fit into the broader drug development process?\n",
    "- What downstream decisions will be based on these results?\n",
    "- How will results be validated in this domain?\n",
    "- What quality control checks are essential?\n",
    "\n",
    "**When Communicating Results:**\n",
    "- What level of technical detail is appropriate for this audience?\n",
    "- How do I convey uncertainty and limitations honestly?\n",
    "- What actions should stakeholders take based on these findings?\n",
    "- Which visualization best supports the key message?\n",
    "\n",
    "---\n",
    "\n",
    "**Next: Python Programming - Implementing Solutions Across All Domains**"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}